Cruise, the self-driving car company owned by General Motors, confirmed to Reuters that its co-founder and chief product officer Daniel Kan has resigned. Kan’s departure comes just a day after the company’s CEO Kyle Vogt announced his resignation on X after a 10-year tenure. Kan is said to have announced his resignation over Slack, however, the reasoning for his departure has not been made clear by the company.
The company’s executive reshuffling follows a public relations nightmare that started last month when a Cruise robotaxi hit a pedestrian in San Francisco and pinned them under the vehicle. The parent company, GM, is still conducting a safety probe on the accident and both autonomous and manual vehicle operations at Cruise remain suspended. The company’s public image has been reeling from the accident ever since, and about 950 robotaxis had to be recalled by GM. The California DMV suspended Cruises’ driverless permits shortly after, and that ruling has remained in place.
(1/6) We learned today at 10:30 am PT of the California DMV’s suspension of our driverless permits. As a result, we will be pausing operations of our driverless AVs in San Francisco. https://t.co/A5HAV2WUv7
In a recent tweet, Cruise said that the company is focused on taking steps “to rebuild public trust.” Things have yet to look up for the company, especially after an expose by The Intercept revealed that the company knew its self-driving cars have trouble recognizing children and large holes in the roads. Furthermore, the former CEO said that the company would have to lay off an undisclosed number of employees and staff members in a memo.
Cruise has not made any statements about finding replacements for either its CEO or chief product officer as of yet. The New York Timesreports that “instead of installing a new chief executive” General Motors has appointed two new members to the company board and Mo Elshenawy, Cruise’s executive vice president of engineering, will take up the role of President.
This article originally appeared on Engadget at https://www.engadget.com/cruise-co-founder-resigns-following-ceo-exit-214747271.html?src=rss
MIT researchers developed an ingestible capsule that can monitor vital signs including heart rate and breathing patterns from within a patient’s GI tract. The scientists also say that the novel device has the potential to also be used to detect signs of respiratory depression during an opioid overdose. Giovanni Traverso, an associate professor of mechanical engineering at MIT who has been working on developing a range of ingestible sensors, told Engadget that the device will be especially useful for sleep studies.
Conventionally, sleep studies require patients to be hooked up to a number of sensors and devices. In labs and in at-home studies, sensors can be attached to a patient’s scalp, temples, chest and lungs with wires. A patient may also wear a nasal cannula, chest belt and pulse oximeter which can connect to a portable monitor. “As you can imagine, trying to sleep with all of this machinery can be challenging,” Traverso told Engadget.
MIT
This trial, which used a capsule made by Celero Systems —A start-up led by MIT and Harvard researchers— marks the first time ingestible sensor technology was tested in humans. Aside from the start-up and MIT, the research was spearheaded by experts at West Virginia University and other hospital affiliates.
The capsule contains two small batteries and a wireless antenna that transmits data. The ingestible sensor, which is the size of a vitamin capsule, traveled through the gastrointestinal tract, and collected signals from the device while it was in the stomach. The participants stayed at a sleep lab overnight while the device recorded respiration, heart rate, temperature and gastric motility. The sensor was also able to detect sleep apnea in one of the patients during the trial. The findings suggest that the ingestible was able to measure health metrics on par with medical-grade diagnostic equipment at the sleep center. Traditionally, patients that need to get diagnosed with specific sleep disorders are required to stay overnight at a sleep lab, where they get hooked onto an array of sensors and devices. Ingestible sensor technology eliminates the need for that.
Importantly, MIT says there were no adverse effects reported due to capsule ingestion. The capsule typically passes through a patient within a day or so, though that short internal shelf life may also limit how effective it could be as a monitoring device. Traverso told Engadget that he aims to have Celetro, which he co-founded, eventually contain a mechanism that will allow the capsule to sit in a patient’s stomach for a week.
Dr. Ali Rezai, the executive chair of the West Virginia University Rockefeller Neuroscience Institute, said that there is a huge potential for creating a new pathway through this device that will help providers identify when a patient is overdosing according to their vitals. In the future, researchers even anticipate that devices could incorporate drugs internally: overdose reversal agents, such as nalmefene, could be slowly administered if a sensor records that a person’s breathing rate slowed or stopped. More data from the studies will be made available in the coming months.
This article originally appeared on Engadget at https://www.engadget.com/mit-tests-new-ingestible-sensor-that-record-your-breathing-through-your-intestines-224823353.html?src=rss
The Google Pixel Fold, released earlier this year, is on sale for $1,399, knocking $400 off its original price of $1,799. This Amazon Black Friday deal marks the lowest price ever on the 256GB model. If you need more storage on your smartphone, the 512GB model is going for $1,519, down from $1,919. The foldable is powered by the Google Tensor G2 and offers 12GB of RAM, making it a great option for those looking to invest in a foldable smartphone as their daily driver. If you're interested in other Black Friday Google Pixel deals, the Pixel 8 and 8 Pro are down to record low prices as well.
The Pixel Fold earned a spot on Engadget’s top foldable phones list, namely for how easy it is to use and for its wide-screen design. Folded, the phone gives you a 5.8-inch screen to work with, and unfolded you get a big, 7.6-inch immersive display. When open, the foldable’s split screen allows you to multitask and do things like shop online and make video calls at the same time. You’re also able to use the main screen and external screen together, letting you take pictures and look at live previews simultaneously. Coming soon is Google Translate’s interpreter mode as well, which allows you to watch translations appear on both screens while you’re talking to another person in a different language.
In terms of camera quality, the Pixel Fold has a lot to offer. The triple rear camera system includes a 48-megapixel main lens, an ultrawide shooter and a telephoto camera with up to 5x optical zoom that delivers sharp photos in daylight and well-exposed photos in the dark. In Engadget’s review, one of its selling points was that the photos beat the competition. When compared to Samsung's Galaxy foldable, Google’s phone delivered images with better shadows and highlights. Notably, even with Samsung’s “food mode” on, Engadget’s Sam Rutherford said the Pixel Fold’s photo chops made food look more appetizing. The phone can also shoot 4K videos at 30 frames per second and 60 frames per second, which is on par with other foldables.
In a landmark decision, the UK’s Medicines and Healthcare products Agency (MHRA) approved the use of a gene-editing therapy called Casgevy for patients with sickle cell disease and beta thalassemia — both of which are hereditary disorders related to genetic mutations of the red blood cells. The treatment, manufactured by Vertex, is the first-ever approved therapy that utilizes CRISPR-based gene editing technology to treat eligible patients.
The UK approval of the novel therapy is informed by two previous global clinical trials that indicated the treatment's efficacy. 97 percent of patients using Casgevy were relieved of severe pain associated with the blood disorders for at least 12 months after treatment during the trials. The results suggest that the gene editing treatment could replace the current standard for care. Stem cell therapy and bone marrow transplants are currently the only pathways to cure sickle cell disease and beta thalassemia, however, they involve a lot of risks.
Both sickle cell disease and beta thalassemia are blood disorders characterized by defective red blood cells that can’t carry oxygen, and require patients to get monthly blood transfusions that can be costly and time-consuming. Casgevy works by specifically targeting the genes in the bone marrow stem cells that produce faulty blood cells. For the treatment to work, a patient’s stem cells need to be extracted from their bone marrow, edited in a lab and then re-infused into the patient.
Despite its promising outlook, CRISPR-based therapies may not be easily available to the general public. Gene editing is an expensive endeavor. The Innovative Genomics Institute (IGI) estimates that the average CRISPR-based therapy will cost between $500,000 and $2 million per patient. The IGI has built out an ‘Affordability Task Force’ to tackle the issue of expanding access to these novel therapies.
Casgevy is still being reviewed by regulatory agencies for safety standards in other countries, including the United States and Saudi Arabia. A marketing application, the first step towards approval for the therapy, was recently validated by the European Medicines Agency.
This article originally appeared on Engadget at https://www.engadget.com/uk-authorizes-first-gene-therapy-for-treating-sickle-cell-disease-184130989.html?src=rss
In a trial run by Verve Therapeutics, a Cambridge–based biotech company, researchers discovered that a single infusion of a gene-editing treatment called VERVE-101 was able to reduce cholesterol levels in patients. This treatment was tested in individuals with hereditary conditions that made them susceptible to developing clogged arteries and heart attacks. Scientists were able to use CRISPR editing techniques to tweak liver gene cells. The researchers “turned off” a cholesterol-raising gene called PCSK9, which is found in the liver, in order to lower LDL-C — sometimes called "bad" cholesterol — which causes plaque to build up in arteries in the first place.
PCSK9 was lowered by as much as 84 percent in the cohorts that received higher infusion rates of the treatment. At those higher treatment doses, Verve scientists said that the reduction of those LDL-C-related proteins lasted 2.5 years in previous studies on primates.
Verve Therapeutics
From a clinical standpoint, this gene editing therapy has the potential to disrupt the current standard treatment for high cholesterol. The current go-to's include prescription statins and PCSK9 inhibitors, but they require strict adherence and can have bad side effects like muscle pain and memory loss.
CRISPR, while seemingly miraculous, is a long way from replacing daily medications though. According to Nature, two of the 10 participants in the study suffered from a “cardiovascular event” that coincided with the infusion. Verve says one was not related to the treatment at all and the second was “potentially related to treatment due to proximity to dosing.” The use of a gene-editing technology will always carry some risk because the edits could occur elsewhere in the genome.
Before a single infusion therapy for high cholesterol can reach consumers, the FDA mandates that the treatment will need to be studied for up to 15 years. Verve recently received FDA clearance for an Investigational New Drug Application for VERVE-101, meaning that the company can begin to conduct trials in the US. The current trials in New Zealand and the United Kingdom will look for willing clinical trial participants to expand the study.
This article originally appeared on Engadget at https://www.engadget.com/researchers-developed-a-gene-editing-technology-that-reduces-bad-cholesterol-170040293.html?src=rss
Synex Medical, a Toronto-based biotech research firm backed by Sam Altman (the CEO of OpenAI), has developed a tool that can measure your blood glucose levels without a finger prick. It uses a combination of low-field magnets and low-frequency radio waves to directly measure blood sugar levels non-invasively when a user inserts a finger into the device.
The tool uses magnetic resonance spectroscopy (MRS), which is similar to an MRI. Jamie Near, an Associate Professor at the University of Toronto who specializes in the research of MRS technology told Engadget that, “[an] MRI uses magnetic fields to make images of the distribution of hydrogen protons in water that is abundant in our body tissues. In MRS, the same basic principles are used to detect other chemicals that contain hydrogen.” When a user’s fingertip is placed inside the magnetic field, the frequency of a specific molecule, in this case glucose, is measured in parts per million. While the focus was on glucose for this project, MRS could be used to measure metabolites, according to the Synex, including lactate, ketones and amino acids.
Synex Medical
Matthew Rosen, a Harvard physicist whose research spans from fundamental physics to bioimaging in the field of MRI, told Engadget that he thinks the device is “clever” and “a great idea.” Magnetic resonance technology is a common technique used for chemical analysis of compounds, however, traditional resonance technologies operate at high magnetic fields and they're very expensive.
Synex found a way to get clear readings from low magnetic fields. “They’ve overcome the challenges really by developing a method that has high sensitivity and high specificity,” Rosen says. “Honestly, I have been doing magnetic resonance for thirty years. I never thought people could do glucose with a benchtop machine… you could do it with a big machine no problem.”
Professor Andre Simpson, a researcher and center director at the University of Toronto also told Engadget that he thinks Synex’s device is the “real deal.” “MRI machines can fit an entire human body and have been used to target molecule concentrations in the brain through localized spectroscopy,” he explained. “Synex has shrunk this technology to measure concentrations in a finger. I have reviewed their white paper and seen the instrument work.” Simpson said Synex’s ability to retrofit MRS technology into a small box is an engineering feat.
As of now, there are no commercially available devices that can measure blood glucose non-invasively. While there are continuous glucose monitors on the market that use microneedles, which are minimally invasive, there is still a risk of infection.
But there is competition in the space for no-prick diagnostics tools. Know Labs is trying to get approval for a portable glucose monitor that relies on a custom-made Bio-RFID sensing technology, which uses radio waves to detect blood glucose levels in the palm of your hand. When the Know Labs device was tested up against a Dexcom G6 continuous glucose monitor in a study, readings of blood glucose levels using its palm sensor technology were “within threshold” only 46 percent of the time. While the readings are technically in accordance with FDA accuracy limits for a new blood glucose monitor, Know Labs is still working out kinks through scientific research before it can begin FDA clinical trials.
Another start-up, German company DiaMonTech, is currently developing a pocket-sized diagnostic device that is still being tested and fine-tuned to measure glucose through “photothermal detection.” It uses mid-infrared lasers that essentially scan the tissue fluid at the fingertip to detect glucose molecules. CNBCand Bloomberg reported that even Apple has been “quietly developing” a sensor that can check your blood sugar levels through its wearables, though the company never confirmed. Founder and CEO of Synex, Ben Nashman, told Engadget that eventually, the company would like to develop a wearable. But further miniaturization was needed before they could bring a commercial product to market.
Rosen says he isn't sure how the sensor technology can be retrofitted for smartwatches or wearables just yet. But he can imagine a world where these tools complement blood-based diagnostics. “Is it good enough for clinical use? I have to leave that for what clinicians have to say.”
Update, November 16 2023, 10:59 AM ET: This story has been updated to clarify that a comment from the company was made by the CEO of Synex and not a company representative.
This article originally appeared on Engadget at https://www.engadget.com/researchers-use-magnetic-fields-for-non-invasive-blood-glucose-monitoring-215052628.html?src=rss
A group of lawmakers from a House of Representatives committee wants Apple, like many Jon Stewart enthusiasts, to explain why its streaming arm abruptly canceled the talk show The Problem With Jon Stewart. The current affairs TV series hosted by Jon Stewart briefly made its debut on Apple TV+ in 2021 but its time on air ended when the show received the ax for a third season, reportedly due to “disagreements” over show topics.
According to Reuters, Lawmakers want to know if the show's coverage and criticism of China has anything to do with the show’s cancellation. The government officials have asked Apple to speak on the issue by Dec 15, 2023.
In a letter to the tech giant, the House members wrote that while Apple has the right to determine what content it deems appropriate for its platform, “the coercive tactics of a foreign power should not be directly or indirectly influencing these determinations.” This effort is bipartisan, with members from both Republican and Democratic parties affiliated with the House of Representatives' Select Committee on Competition with the Chinese Communist Party.
“As China is to America, Texas is to Illinois” - @JonStewart on how corporations pit states against each other to offer the fewest worker protections and biggest tax incentives. pic.twitter.com/q6L1lSjoPx
— The Problem With Jon Stewart (@TheProblem) July 27, 2023
Roughly 19 percent of Apple sales come from China, with over $72.5 billion in net sales reported for the company’s fiscal 2023, which closed in September. It might make sense that the company would avoid streaming a show with strong political opinions that could impact its bottom line in such a significant way. But the show discussed several hot-button topics, including artificial intelligence and gun control. According to the New York Times, sources familiar with the matter said that, beyond discussions about China, the show’s criticism of topics like artificial intelligence played a role in the decision to cut the show.
This article originally appeared on Engadget at https://www.engadget.com/lawmakers-question-apple-over-cancellation-of-jon-stewarts-show-192316298.html?src=rss
A machine learning-based weather prediction program developed by DeepMind researchers called “GraphCast” can predict weather variables over the span of 10 days, in under one minute. In a report, scientists highlight that GraphCast has outperformed traditional weather pattern prediction technologies at a 90% verification rate.
The AI-powered weather prediction program works by taking in “the two most recent states of Earth’s weather,” which includes the variables from the time of the test and six hours prior. Using that data, GraphCast can predict what the state of the weather will be in six hours.
In practice, AI has already showcased its applicability in the real world. The tool predicted the landfall of Hurricane Lee in Long Island 10 days before it happened, while the traditional weather prediction technologies being used by meteorologists at the time lagged behind. Forecasts made by standard weather simulations can take longer because traditionally, models have to account for complicated physics and fluid dynamics to make accurate predictions.
Not only does the weather prediction algorithm outperform traditional technologies to forecast weather patterns in terms of pace and scale, GraphCast can also predict severe weather events, which includes tropical cyclones and waves of extreme temperatures over regions. And because the algorithm can be re-trained with recent data, scientists believe that the tool will only get better at predicting oscillations in weather patterns that coincide with grander changes that align with climate change.
Soon, GraphCast, or at least the basis of the AI algorithm that powers its predictions, might pop up into more mainstream services. According to Wired, Google might be exploring how to integrate GraphCast into its products. The call for better storm modeling has already paved a path for supercomputers in the space. The NOAA (National Oceanic and Atmospheric Administration) says it has been working to develop models that will provide more accurate readings on when severe weather events might occur and importantly, the intensity forecasts for hurricanes.
This article originally appeared on Engadget at https://www.engadget.com/ai-is-starting-to-outperform-meteorologists-173616631.html?src=rss
Subscriptions to the Headspace app are half off this Black Friday for new and returning customers who have had memberships expire. Starting on November 14 through the 27th, the annual $70 fee will be slashed to $35. Alternatively, you could get a monthly subscription for $6.50 each pay period instead of $13.
A subscription to the mindfulness app will get you access to an entire suite of meditation programming, as well as sounds that can help you focus. But the app isn’t just for stress — it landed a spot on our best sleep app list. Users will also gain access to curated yoga and fitness videos that can help them stick to their fitness goals and in turn, improve overall wellness.
Headspace also offers video content and stress-relieving meditation programs specific for work and school. You can calm your nerves and learn how to connect with your peers by taking the advice of a professional before a presentation if you struggle with public speaking, for example. Or you could follow along with a 7-minute meditation clip to help you decompress after a long day at work. If you're new to meditation, you can start as a beginner through a four-week guided program assembled by a Headspace expert.
If you're navigating change or undergoing a stressful time, this Black Friday deal might be the perfect gateway into meditation and getting extra mental health support. If you're thinking about shopping for the holidays, Engadget has recommended a subscription to Headspace app as a thoughtful gift for teachers, or students alike.
This article originally appeared on Engadget at https://www.engadget.com/headspaces-black-friday-deal-knocks-half-off-annual-and-monthly-memberships-140017944.html?src=rss
If you've been waiting for a reason to finally grab a headset to watch 360-degree videos on YouTube or have an exceptionally immersive experience with first-person shooter games, Amazon’s early Black Friday sale on the Meta Quest 2 VR headset might be your gateway into the world of VR. The Quest 2 with 128GB of storage is getting a $50 price cut in a Black Friday pre-sale, bringing it to $250. This record low price, which normally sells for $300, is worth considering, especially since Engadget hailed it as one of the best VR headsets your money can buy.
Despite being an older model, we still consider the Meta Quest 2 the best budget VR headset, and for good reason. Most competitors, including its successor, start at around $500 and can go for as much as $1000. The Quest 2’s screen resolution of 1832x1920 per eye, when coupled with a 90Hz refresh rate, makes activities like gaming a more pleasurable experience. And because the Quest 2 operates using Qualcomm's Snapdragon XR2 processor and packs 6GB of RAM, the device can dabble with more demanding games. If you are already a console user, things like Xbox Cloud gaming pair quite nicely.
The Quest 2 Active bundle, which includes the 128GB headset and accessories for VR workouts, is also on sale on Amazon for $319. But if you want to go big and invest in the 256GB version of the Quest 2, Amazon’s deal on that model will make the device $300, knocking off $50 bucks from its $350 starting point.
This article originally appeared on Engadget at https://www.engadget.com/the-meta-quest-2-vr-headset-drops-to-an-all-time-low-of-250-during-amazons-early-black-friday-sale-181828211.html?src=rss